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Abstract
Introduction The identification of potential breast cancer stem
cells is of importance as the characteristics of stem cells
suggest that they are resistant to conventional forms of therapy.
Several techniques have been proposed to isolate or enrich for
tumorigenic breast cancer stem cells, including (a) culture of
cells in non-adherent non-differentiating conditions to form
mammospheres and (b) sorting of the cells by their surface
phenotype (expression of CD24 and CD44).
Methods We have cultured metastatic cells found in pleural
effusions from breast cancer patients in non-adherent
conditions without serum to form mammospheres. Dissociated
cells from these mammospheres were used to determine the
tumorigenicity of these cultures. Expression of CD24 and CD44
on uncultured cells and mammospheres derived from the pleural
effusions was documented.
Results We found that the majority (20/27) of the pleural
effusions tested contained cells capable of forming
mammospheres of varying sizes that could be passaged. After
dissociation and plating with serum onto adherent dishes, the
cells can differentiate, as determined by the increased
expression of cytokeratins and MUC1. Analysis of surface
expression of CD24 and CD44 on uncultured cells from 21 of
the samples showed that the cells from some samples
separated into two populations, but some did not. The
proportion of cells that could be considered CD44+/CD24low/-
was highly variable and did not appear to correlate with the
ability to form the larger mammospheres. Of eight pleural
effusion mammospheres tested in severe combined
immunodeficiency disease (SCID) mice, four were found to
induce tumours when only 5,000 or fewer cells were injected,
whereas the same number of uncultured cells did not form
tumours. The ability to induce tumours appeared to correlate
with the ability to produce the larger mammospheres.
Uncultured cells from a highly tumorigenic sample (PE14) were
uniformly negative for surface expression of both CD24 and
CD44.
Conclusion This paper shows, for the first time, that
mammosphere culture of pleural effusions enriches for cells
capable of inducing tumours in SCID mice. The data suggest
that mammosphere culture of these metastatic cells could
provide a highly appropriate model for studying the sensitivity of
the tumorigenic 'stem' cells to therapeutic agents and for further
characterisation of the tumour-inducing subpopulation of breast
cancer cells.
Introduction
It is now clear that normal adult tissues are maintained by the
controlled proliferation of stem cells that give rise to progenitor
cells producing differentiated progeny [1]. In the mouse mam-
mary gland, the presence of stem cells has been clearly dem-
onstrated by showing that single cells can repopulate a
cleared fat pad [2-5]. These cells, termed mammary repopulat-
ing units (or MRUs), are found in a ratio of 1:1,400 mammary
epithelial cells. Although a similar approach has not yet identi-
fied MRUs in human breast epithelial cells, other approaches
CK = cytokeratin; ESA = epithelial specific antigen; FCS = foetal calf serum; MRU = mammary repopulating unit; PBS = phosphate-buffered saline; 
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indicate that pluripotent stem cells are present in the human
mammary ductal tree. Thus, by analogy with studies on neuro-
nal stem cells, Dontu and colleagues [6] developed a culture
system in which cells derived from reduction mammoplasties
were seeded in non-adherent non-differentiating culture con-
ditions. Cells capable of surviving and proliferating in such
conditions formed discrete clusters of cells termed 'mammos-
pheres'. Such spheroids were enriched in progenitor cells
capable of differentiating along multiples lineages (that is,
luminal, myoepithelial, and alveolar).
The concept that the growth of tumours is also based on the
division of a stem cell giving rise to differentiated progeny is
also receiving considerable support. The development of a
tumour could then be due to an imbalance in the symmetric
versus asymmetric division of the stem cell, or to phenotypic
changes in progeny, which bestow stem cell properties on
these cells that normally have a finite life span. The importance
of this concept lies in the possible difference in the phenotype
of the stem cell, which could allow them to evade killing by the
existing therapies [7]. In breast cancer, the mammosphere cul-
ture system has now been used to identify, and enrich for,
putative stem cells using breast cancer cell lines [8-10], a few
oestrogen receptor-positive primary invasive breast tumours
[10], and ductal carcinoma in situ [11]. However, mammos-
pheres have not been cultured from distant metastases.
An alternative approach has been to attempt to define the sur-
face phenotype of cells that induce tumours in immune-sup-
pressed mice upon injection of very low cell numbers. Taking
this approach, Al-Hajj and colleagues [12] described the iso-
lation of breast cancer cells from pleural effusions, which
could form tumours in severe combined immunodeficiency
disease (SCID) mice by sorting for potential stem cell markers.
As few as 100 cells classified as CD44+ CD24low/- could form
tumours. Significantly, Ponti and colleagues [10] found that
95% to 96% of cells in mammospheres cultured from cell lines
and primary breast tumours stained negatively for CD24. How-
ever, the expression of CD44 and CD24 in uncultured primary
cell isolates was not reported.
Here, we have examined the ability of metastatic cells in pleu-
ral effusions from late-stage breast cancer patients to form
mammospheres and determined the in vivo tumorigenicity of
some mammospheres that could be passaged in vitro. We
also examined the surface expression of CD44 and CD24 by
uncultured cells, using flow cytometric analysis, to attempt to
correlate the presence of a CD44+/CD24low/- phenotype with
the ability to form mammospheres and with the tumorigenic
potential of the mammosphere cells.
Our data indicate that mammosphere culture of metastatic
breast cancer cells from pleural effusions (some of which have
been frozen for more than 20 years) can enrich for tumorigenic
cells. The data also suggest that this form of culture, since it
enriches for the putative tumorigenic cell, is a feasible
approach for isolating these cells for characterisation.
Materials and methods
Isolation of cells from pleural effusions
Cells were pelleted by centrifuging pleural fluid diluted with
RPMI medium, and the pellet was washed twice with phos-
phate-buffered saline (PBS), before suspension in RPMI
medium without serum. Cells were then collected from the
interface after centrifuging over a Ficoll density gradient. Work
with pleural effusions was carried out with Central Office for
Research Ethics (COREC) approval number 05/Q0704/63.
Mammosphere culture
Single-cell suspensions of cell lines or cells isolated from pleu-
ral effusions were suspended at a density of 40,000 cells per
millilitre in Dulbecco's modified Eagle's medium/F-12 contain-
ing 5 mg/mL insulin, 0.5 mg/mL hydrocortisone, 2% B27 (Inv-
itrogen Ltd., Paisley, Scotland), and 20 ng/mL epidermal
growth factor and seeded into six-well plates (2.5 mL per
plate) or T80 tissue culture flasks (10 mL per flask) coated
with 1.2% polyhema. Cultures were fed weekly and passaged
every 2 weeks. Mammospheres were measured using Zeiss
Axiovision software (Carl Zeiss, Jena, Germany). When pas-
saged, mammospheres were harvested, incubated with
trypsin for 3 minutes at 37°C, and dispersed by pipetting with
a 23-gauge needle. After checking for single cells, the cells
were pelleted and suspended in mammosphere culture
medium to 40,000 cells per millilitre before replating in non-
adherent plates or flasks.
Differentiation of mammosphere cells
Disaggregated mammospheres were seeded on glass cover-
slips in mammosphere medium supplemented with 1% foetal
calf serum (FCS). Cells were allowed to adhere and differenti-
ate for 5 days before fixing and staining.
Immunofluorescent staining
Parental cells and differentiated mammosphere-derived cells
grown on glass coverslips or mammospheres in suspension
were fixed in 4% paraformaldehyde for 10 minutes, washed in
PBS, and then permeabilised in 0.1% triton for 5 minutes.
After further washing in PBS, cells were incubated for 1 hour
at room temperature with neat primary antibody SWA11 (a
kind gift from Peter Altevogt) [13], cytokeratin 14 (CK14) [14],
CK19 [15], and HMFG2 [16,17] supernatants. Following a
wash in PBS, the cells were incubated for 1 hour at room tem-
perature in secondary antibody Alexa 488-conjugated rabbit
anti-mouse (Molecular Probes, now part of Invitrogen Corpo-
ration, Carlsbad, CA, USA) diluted 1:500 in PBS. Cells were
washed with PBS before coverslips were air-died and mam-
mospheres stained in suspension were spun-down with all
supernatant removed. Coverslips and cells were then stained
and mounted with 10 mg/mL DAPI (4,6-diamidino-2-phenylin-
dole dihydrochloride) (Sigma-Aldrich, Poole, UK) in aqueousAvailable online http://breast-cancer-research.com/content/10/3/R52
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mountant (Dako 2972; DakoCytomation, Glostrup, Denmark)
and viewed under a Zeiss fluorescence microscope (Carl
Zeiss).
Flow cytometry
For the detection of CD24low/- CD44+ populations in uncul-
tured pleural effusions, cells were stained in 96-well plates in
a volume of 50 μL with 2 μL per well of each monoclonal anti-
body: CD24.PE (ML5), CD44.FITC (G44-26), and
ESA.PcPCy5 (BD Biosciences, San Jose, CA, USA). Isotype-
matched labelled controls were also used in the analysis. Cells
were labelled on ice for 30 minutes and washed twice before
analysis in the cytometer.
For comparison of ML5 and SWA11 [13] antibodies for
detection of CD24 on uncultured pleural effusion cells, uncon-
jugated antibodies SWA11 (antibody supernatant, generous
gift from Peter Altevogt) and ML5 (BD Biosciences) were
used at 1:30 dilution and neat, respectively, and detected by
a fluorescein isothiocyanate-conjugated rabbit anti-mouse
secondary antibody diluted 1:100 (DakoCytomation). Incuba-
tion was carried out for 45 minutes on ice per antibody with
two washes after each incubation. PBS supplemented with
0.5% bovine serum albumin was used for antibody dilution,
washes, and resuspension of the cells. Cells were analysed on
an Epics XL (Beckman Coulter, Fullerton, CA, USA).
Mice and tumour challenge
Female SCID (CB17/ICR-Prkdc SCID/crl) mice, 7 weeks old,
were intraperitonealy injected with 0.2 mg etoposide. Seven
days later, cells resuspended in matrigel/RPMI were injected
subcutaneously in the flank region. Mice were examined every
2 days for the appearance of a tumour, which was measured
with callipers. When tumours reached 1.4 cm2, they were
taken and placed in 4% paraformaldehyde. All animal work
was performed under Home Office guidelines and under
project licence number 70/4701.
Immunoperoxidase staining
Xenograft tumours were fixed in formal saline and processed
to paraffin wax, and 3-μm sections were cut using a micro-
tome. After sections were air-dried overnight, they were
dewaxed in xylene and dehydrated in alcohol. The sections
were stained with the following antibodies: anti-keratin 14
(Biogenics, Napa, CA, USA), anti-keratin 19 (BA17 [15];
DakoCytomation), HMFG1 [16,17], HMFG2 [16,17], and
SWA11 [13] using the DakoCytomation REAL™ EnVision™
detection system according to the manufacturer's instructions.
When staining with anti-CK14 and anti-CK19, antigen
retrieval was performed by pressure-cooking for 2 minutes in
citrate buffer (pH 6.0) (DakoCytomation).
Results
Mammosphere culture of metastatic breast cancer cells 
from pleural effusions
Single-cell suspensions derived from pleural effusions from 27
breast cancer patients or ascites from 5 breast cancer
patients were placed in mammosphere culture. Most of the
samples had been frozen for more than 20 years, although five
cultures were from fresh specimens of pleural effusions col-
lected in 2006 (designated 06 followed by the PE number in
Table 1). Twenty out of 27 pleural effusion samples (74%) pro-
duced viable mammospheres (20 to 100 μm) that could be
cultured past passage 2 (Table 1). In many cases, these could
be passaged further. However, no ascites samples produced
viable mammospheres beyond a second passage (0/5). Fig-
ure 1a shows mammospheres cultured from four samples, and
for comparison, the mammospheres produced by three breast
cancer cell lines are shown in Figure 1c. Only the two epithe-
lial cell lines produced discrete relatively large mammos-
pheres, which could be passaged. The fibroblastic-like cell line
MDA-MB-231 formed small loosely adherent structures,
which, however, did survive passaging.
To determine whether mammosphere-cultured cells from pleu-
ral effusions taken from late-stage breast cancer patients
could differentiate into multiple lineages, cells were placed in
differentiating conditions and then stained for lineage markers.
In the normal breast, different keratins predominate in the dif-
ferent lineages, with CK18 and CK19 being expressed in the
luminal cells and CK5 and CK14 in basal/myoepithelial cells.
Mammospheres were disrupted, and single cells were plated
on glass coverslips in medium supplemented with 1% FCS
and after 5 days were stained with antibodies to keratins 5, 14,
and 19 and to the luminal cell marker MUC1. While cells from
uncultured pleural effusion samples were not viable under
these culture conditions, pleural effusion cells that had been
cultured first as mammospheres survived. Figure 1b shows
that differentiated PE14 mammosphere-derived cells showed
higher expression of CK5, CK14, and CK19 compared with
undifferentiated mammospheres (Figure 1b). The MUC1
membrane mucin expressed by luminal epithelial cells and by
the bulk population of most breast tumours was also not
expressed in mammospheres, but expression was induced
after transferring the disrupted mammospheres to adherent
plates in the presence of serum (Figure 1b).
CD44 and CD24 expression by uncultured cells and 
growth of mammospheres from cells in pleural effusions 
from breast cancer patients
A CD44+  CD24low/-  population was isolated from breast
tumours and pleural effusions by Al-Hajj and colleagues [12]
and these cells were found to be enriched with tumorigenic
cells. In these experiments, cells were sometimes gated for
epithelial specific antigen-positive (ESA+) cells, and there was
a suggestion that the ESA+ subset of CD44+/CD24low/- cells
were more tumorigenic. Using the same CD24 antibody usedBreast Cancer Research    Vol 10 No 3    Grimshaw et al.
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by Al Hajj and colleagues [12] (ML5) and the same CD44 anti-
body, we found that only some pleural effusion samples
yielded subfractions of cells and these could be detected
whether or not the cells were first gated as ESA+ (data not
shown). We therefore proceeded to analyse the samples with-
out gating for ESA. We also checked whether there was any
difference in staining for CD24 using the SWA11 antibody,
which is reactive with all glycoforms of CD24, and ML5, the
antibody used by Ponti and colleagues [10] and Al-Hajj and
colleagues [12]. Figure 2 shows that, for six pleural effusion
samples, we found that SWA11 did not give a stronger signal
or detect more CD24+ cells. All the samples were therefore
analysed using the phycoerythrin-conjugated ML5 antibody
(see Materials and methods).
Figure 3 records the fluorescence-activated cell sorting pro-
files of uncultured cells stained with antibodies to CD24 and
CD44 for 21 of the 27 samples of pleural effusions. The data
Table 1
Surface phenotype and mammosphere culture of cells from pleural effusions
Sample Average size of mammospheres (μm) Population of CD44+/CD24low/- cells (percentage)
PE33 No mammospheresa 14.2
PE61 No mammospheres
PE70 No mammospheres 37
PE75 No mammospheres 62
PE77 No mammospheres 18.8
PE78 No mammospheres 10.4
PE89 No mammospheres
PE19 20 67.9
PE20 20 0.3
PE22 20
PE23 20 65
PE62b 20 13.2
PE63 20
PE88b 20 37
PE6b 30 1.5
PE79 40 4.8
PE11 50 26
PE43b 50 9.9
06PE5c 50
06PE7c 50
PE73 60 29.4
06PE4c 60 4.9
06PE8b,c 70 70.6
PE14b 100 Uncultured cells uniformly CD44- and CD24-
PE21 100 3.3
06PE6b,c 100 15.3
PE66b 130 6.85
Cells from pleural effusion (PE) samples taken from breast cancer patients were tested for their ability to form mammospheres. Uncultured cells 
were analysed for surface expression of CD24 and CD44 (Figure 3). a7/27 (26%) did not make mammospheres or could not be passaged 
beyond passage 2. bTested for tumorigenicity in severe combined immunodeficiency disease mice (Table 2). cFive samples obtained in 2006 
were placed into culture without freezing. The other 22 samples obtained from 1977 to 1984 had been stored in liquid nitrogen.Available online http://breast-cancer-research.com/content/10/3/R52
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show that in several samples two distinct populations can be
recognised (for example, PE06/8, PE88, and PE70), whereas
with other samples this is not the case. Moreover, CD44+/
CD24low/- cells were often within a subpopulation and existed
only as a discrete defined subset in some samples (for exam-
ple, PE23 and PE75). Inserting the cutoff values from the con-
trol antibody analysis, the cells in the bottom righthand
quadrant were considered as CD44+/CD24low/-, and the per-
centage for each sample is listed in Table 1 and Figure 3.
Comparing the ability to form mammospheres and the size of
the mammospheres produced with the presence of a CD44+/
CD24low/- population as defined in this way showed no obvi-
ous correlation with the ability of the cells to form mammos-
pheres or with the size of the mammosphere produced (Table
1).
The flow profile of the PE14 sample was particularly striking as
surface expression of CD24 and CD44 by the uncultured cells
was uniformly negative (Figure 3). Moreover, mammospheres
from this sample were large and could be extensively pas-
saged. Staining of PE14 mammospheres for CD24 with either
the SWA11 or ML5 antibody showed that CD24 was low or
absent (Figure 4a), as was also observed by Ponti and col-
leagues [10] in mammospheres cultured from recurrent breast
Figure 1
Metastatic cells from pleural effusions isolated from breast cancer patients can form mammospheres Metastatic cells from pleural effusions isolated from breast cancer patients can form mammospheres. (a) Cells were isolated from pleural effusions 
(PEs) and placed in non-differentiating medium in non-adherent culture flasks (see Materials and methods). PE14, PE6, PE21, and PE8 show four 
representative cultures. (b) PE mammospheres were disrupted and the cells plated onto glass coverslips in medium supplemented with 1% foetal 
calf serum. After 5 days of adherent culture, the cells were stained with antibodies to MUC1 (HMFG2), CK5 (D5/6), CK14 (LL002), and CK19 
(BA17). (c) Breast cancer cell lines were also placed in non-differentiating medium in non-adherent culture flasks. Mammospheres could be seen 
developing in MCF7 and SKBR3 cultures, while MDAMB231 produced loosely adhered clumps of cells.Breast Cancer Research    Vol 10 No 3    Grimshaw et al.
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cancer or MCF7 cells. As with the lineage markers, expression
was increased upon differentiation (Figure 4b).
Tumour growth in vivo
To assess tumorigenic potential, cells from mammospheres
from selected samples (governed by availability) were injected
into SCID mice (Table 2). The mammospheres were gently
disrupted by pipetting and resuspended in matrigel solution.
Cells were injected into the flank of mice that had been previ-
ously injected intraperitonealy with etoposide solution, but the
mice did not receive oestrogen implants. Unsorted/uncultured
cells were injected as a control. The number of cells available
for injection restricted the number of mice and the number of
cells that could be injected. To obtain the data shown in Table
2, 5,000 cells from mammospheres or uncultured cells from
eight samples were injected per mouse. Whereas four of the
samples tested in this way produced tumours, uncultured cells
from these samples did not (Figures 5a and 5b and Table 2).
Figures 5a and 5b show the tumour development in mice
injected with 5,000 cells from mammospheres grown from
samples PE14 and PE66. Cells from PE14 mammospheres
were extremely tumorigenic and cell dilution experiments
showed that tumours could be produced from as few as 500
cells (Figure 5c).
Table 2 shows that of the four samples that induced tumours,
all produced mammospheres larger than 50 μm; however,
tumorigenicity did not correlate with the percentage of
CD44+/CD24low/- cells in the original population. Uncultured
cells from the fourth sample, PE14, showed the unusual fea-
ture of expressing no surface CD24 or CD44. Moreover,
tumours isolated from the mouse did not express these com-
ponents either, nor did they express the lineage markers
MUC1 or CK14 (Figure 5d) in accordance with the pathology
of the tumours, which showed no indication of differentiation
but a high percentage of mitoses. Weak keratin 19 expression
was detected (Figure 5d), and while this is a luminal marker, it
has been reported to be expressed by stem cells [18].
Discussion
The hypothesis that tumours arise in the stem cells of tissues
rather than the differentiated cell lineages is not new [19,20],
but it is only recently that the tools have become available to
evaluate this hypothesis. [21,22]. Two of the major challenges
in these studies, particularly in breast cancer, are (a) to identify
breast cancer stem cell markers and (b) to isolate the presum-
ably limited number of cells that can recapitulate a breast
tumour  in vivo. CD24low/-  CD44+  has been suggested to
define a population of cells that contain potential breast can-
cer stem cells [12], as has high expression of α-6 integrin [8].
On the other hand, culturing cells in so-called 'mammosphere
culture' has been proposed as a method for enriching the pro-
genitor cell pool in vitro. With this background, we examined
cells in samples of pleural effusions for the presence of a
CD44+/CD24low/- subpopulation and for their ability to grow in
non-adhesive conditions as mammospheres. While cells with
a CD44+/CD24low/- phenotype could be detected in some
samples, the percentage of such cells was highly variable
between samples. In some cases, the CD44+/CD24low/- phe-
notype formed a discrete population, but in others the
phenotype was absent or was part of a larger subgroup. More-
over, the ability to form the larger mammospheres did not
appear to correlate with the percentage of cells with this phe-
notype but did correlate with the ability of the mammosphere
cells to induce tumours in SCID mice. Our data suggest that
Figure 2
CD24 expression by pleural effusion cells as detected by antibodies SWA11 and ML5 CD24 expression by pleural effusion cells as detected by antibodies SWA11 and ML5. Cells isolated from pleural effusions were stained with 
unconjugated SWA11 and ML5, and antibody binding was detected by fluorescein isothiocyanate-conjugated rabbit anti-mouse secondary antibody 
(see Materials and methods). Filled histograms, 2° antibody only; thin grey line, SWA11; thick black line, ML5. PE, pleural effusion.Available online http://breast-cancer-research.com/content/10/3/R52
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enrichment of tumorigenic cells from the bulk tumour popula-
tion may be most readily achieved by mammosphere culture.
It is of note that the majority of the samples examined had been
stored in liquid nitrogen for more than 20 years. Although most
of these samples were able to generate mammospheres (17/
22), the majority were small in size (<50 μm). Of these 17,
seven pleural effusion samples gave rise to mammospheres
that had an average diameter of only 20 μm, which may be on
the borderline of the definition of a mammosphere.
Nevertheless, mammospheres larger than 50 μm were gener-
ated from five of these stored samples, two of which were
shown to induce tumours in SCID mice (PE66 and PE14).
Samples collected recently and cultured directly (06 series) all
Figure 3
CD24 and CD44 expression by pleural effusion cells CD24 and CD44 expression by pleural effusion cells. Cells isolated from pleural effusions were analysed for their expression of CD44 and CD24 by 
flow cytometry using antibody clone G44-26 conjugated to fluorescein isothiocyanate to detect CD44 and using the ML5 antibody conjugated to 
phycoerythrin to detect CD24 (see Materials and methods). Control analyses were performed with an isotype-matched antibody. This is shown for 
the sample PE14 (Iso) along with the analysis with CD44 and CD24 antibodies (Test). For the other samples, the lines to form the quadrants were 
applied based on the analysis with the control antibody. The percentages in the right bottom quadrant refer to the CD44+ CD24low/- population. PE, 
pleural effusion.Breast Cancer Research    Vol 10 No 3    Grimshaw et al.
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gave mammospheres of a reasonable size (≥ 50 μm) and the
two tested induced tumours in mice. Thus, although the stored
tumour cells from some samples were highly proliferative and
tumorigenic, some produced no mammospheres or were
small. The results suggest that in the unfrozen samples col-
lected recently, the survival of the tumour-inducing mammos-
phere-producing cells may have been more consistent than in
the stored samples. If this is so, freezing could have affected
the recovery of the CD44+/CD24low/- cells in some samples. It
may be that conditions for freezing the tumorigenic cells need
to be optimised if samples are to be frozen.
One of the stored pleural effusions, PE14, which formed large
mammospheres (average 100 μm) that were highly tumori-
genic, showed an unusual phenotype in that all of the cells in
the uncultured population were negative for surface expres-
sion of CD24 and CD44. The fact that all the cells were neg-
ative for CD24 could indicate that the stem cell was highly
imbalanced toward symmetrical cell division. The absence of
the CD44 surface marker was unexpected but could reflect
the true phenotype of the cancer stem cell, the CD24low/-
CD44+ profile reflecting the phenotype of progenitor cells. The
tumours developing in the mouse injected with PE14 mam-
mosphere cells also showed no expression of CD24 or of
most lineage markers, being in agreement with the pathology,
which showed an undifferentiated highly mitotic tumour. Weak
expression of keratin 19 was detected in the PE14 mouse
tumours, but this has also been reported to be a marker for the
cancer stem cell [18]. The fact that tumours were not induced
by low numbers of uncultured PE14 cells, however, indicates
that selection for the tumorigenic cells has occurred in the
mammosphere culture. In contrast to the phenotype of the
tumours in the mice, the pluripotency of the PE14 mammos-
phere cells could be demonstrated by culturing them under
differentiating conditions, when the class lineage markers
were expressed.
Conclusion
This report demonstrates the presence in metastatic pleural
effusions from breast cancer patients of cells capable of form-
ing mammospheres that after dissociation can differentiate,
expressing markers of both luminal and basal cells. Some of
these mammospheres have the ability to form tumours in SCID
Figure 4
CD24 expression in mammospheres CD24 expression in mammospheres. (a) Mammospheres from pleural 
effusion PE14 and (b) cells from disrupted PE14 mammospheres dif-
ferentiated in the presence of serum were stained for CD24 expression 
using the SWA11 antibody, and binding was visualised using rabbit 
anti-mouse Alexa 488-conjugated antibody (left panels). Right panels 
are the same cells stained with DAPI (4,6-diamidino-2-phenylindole 
dihydrochloride). PE, pleural effusion.
Table 2
Tumorigenicity of cells from pleural effusion mammospheres
Sample Average size of mammospheres (μm) Percentage of CD44+/CD24low/- cells Tumorigenicity
PE88 20 37 0/3a
PE62 20 13.2 0/3
PE6 30 1.5 0/3
PE43 50 9.9 0/3
06PE8 70 70.6 4/7
06PE6 100 15.3 1/3
PE14 100 All cells CD24- and CD44- 5/7
PE66 130 6.8 1/3
Mice were injected with 5,000 cells from disrupted mammospheres as described in Materials and methods. aThe ratio of mice developing tumours 
over mice injected. PE, pleural effusion.Available online http://breast-cancer-research.com/content/10/3/R52
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mice after the injection of very small numbers of cells (in one
case, as low as 500), which appears to correlate with the size
of the mammosphere. Xenograft models of human breast can-
cer have traditionally been very hard to establish and maintain.
The high success rate for culturing accessible metastatic
breast cancer cells as mammospheres suggests that mam-
mosphere culture could provide a highly appropriate model for
studying the sensitivity of the tumorigenic 'stem' cells in the
tumour to therapeutic agents. A comparison of efficacy using
mammospheres from breast cancer cell lines or mammos-
pheres cultured from individual pleural effusions as targets
would allow evaluation of the consistency of effectiveness of a
specific therapy.
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Figure 5
Mammosphere-derived cells from pleural effusions are tumorigenic Mammosphere-derived cells from pleural effusions are tumorigenic. Five thousand uncultured or mammosphere-derived cells were injected into 
severe combined immunodeficiency disease mice, and tumour development was monitored. Survival graphs for PE14 (a) and PE66 (b) are shown. 
(c) Survival curves of mice injected with different numbers of cells (as indicated) derived from PE14 mammospheres. (d) Tumours derived from cells 
isolated from PE14 mammosphere cultures were removed, fixed, sectioned, and stained for CD24 (SWA11), MUC1, and CK14 and CK19 expres-
sion, as described in Materials and methods. CK, cytokeratin; H&E, haematoxylin and eosin; ms, mammosphere; PE, pleural effusion.Breast Cancer Research    Vol 10 No 3    Grimshaw et al.
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